Today, the standards of BC treatment are based on determining the tumor's biological phenotype through analysis of established markers: estrogen receptor (ER), progesterone receptor (PR), human epidermal grows factor receptor 2 (HER2/neu), and marker of proliferation Kiel 67 (Ki67). This evidence concerns the gene PGR and neoplasm.